Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 2/2020

01.02.2020 | Focussed Research Review

Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer

verfasst von: Morten Orebo Holmström, Sabrina Cordua, Vibe Skov, Lasse Kjær, Niels Pallisgaard, Christina Ellervik, Hans Carl Hasselbalch, Mads Hald Andersen

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin (CALR) exon 9 mutations are driver mutations in patients with chronic myeloproliferative neoplasms (MPN), which are chronic blood cancers. The CALR mutations generate a neo-antigen that is recognized by patient T cells, and T cells isolated from a patient with a CALR-mutation can recognize and kill autologous CALR-mutant cells. Surprisingly, healthy individuals display frequent and strong T cell responses to the CALR neo-antigens too. Furthermore, healthy individuals display immune responses to all parts of the mutant CALR epitope, and the CALR neo-epitope specific responses are memory T cell responses. These data suggest that although healthy individuals might acquire a CALR mutation, the mutant cells can be eliminated by the immune system. Additionally, a small fraction of healthy individuals harbor a CALR exon 9 mutation. Four healthy individuals carrying CALR mutations underwent a full medical examination including a bone marrow biopsy after a median follow up of 6.2 years. None of these patients displayed any signs of CALR-mutant MPN. Additionally, all healthy individuals displayed strong CALR neo-epitope specific T cell responses suggesting that these healthy individuals retained their CALR-mutant cells in the editing stage for several years. Thus, we suggest that CALR-mutant MPN could be a disease model of cancer immuno-editing, as we have demonstrated that CALR-mutant MPN displays all three stages described in the theory of cancer immuno-editing.
Literatur
6.
Zurück zum Zitat Posthuma EF, Falkenburg JH, Apperley JF et al (1999) HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood 93:3863–3865PubMed Posthuma EF, Falkenburg JH, Apperley JF et al (1999) HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood 93:3863–3865PubMed
8.
14.
Zurück zum Zitat Qin H, Chen W, Takahasi M et al (1995) CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res 55:2984–2987PubMed Qin H, Chen W, Takahasi M et al (1995) CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res 55:2984–2987PubMed
20.
Zurück zum Zitat Takahashi M, Chen W, Byrd DR et al (1995) Antibody to ras proteins in patients with colon cancer. Clin Cancer Res 1:1071–1077PubMed Takahashi M, Chen W, Byrd DR et al (1995) Antibody to ras proteins in patients with colon cancer. Clin Cancer Res 1:1071–1077PubMed
22.
Zurück zum Zitat Butt NM, Rojas JM, Wang L et al (2005) Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. Haematologica 90:1315–1323PubMed Butt NM, Rojas JM, Wang L et al (2005) Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. Haematologica 90:1315–1323PubMed
28.
Zurück zum Zitat Greiner J, Schneider V, Schmitt M et al (2013) Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). Blood 122:1087–1088CrossRefPubMed Greiner J, Schneider V, Schmitt M et al (2013) Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). Blood 122:1087–1088CrossRefPubMed
40.
Zurück zum Zitat Keilholz U, Weber J, Finke JH et al (2002) Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25:97–138CrossRefPubMed Keilholz U, Weber J, Finke JH et al (2002) Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25:97–138CrossRefPubMed
Metadaten
Titel
Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer
verfasst von
Morten Orebo Holmström
Sabrina Cordua
Vibe Skov
Lasse Kjær
Niels Pallisgaard
Christina Ellervik
Hans Carl Hasselbalch
Mads Hald Andersen
Publikationsdatum
01.02.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 2/2020
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-019-02473-y

Weitere Artikel der Ausgabe 2/2020

Cancer Immunology, Immunotherapy 2/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.